Suanfarma Suanfarma

X

Find the latest Drugs in Development and Pipeline Prospector News of National Eye Institute.

Client Virtual Booth
  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
National Eye Institute
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
31 Center Drive MSC 2510 Bethesda, MD 20892-2510
Telephone
Telephone
301-496-5248

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The grant will be used for the development of IVMED-85, an investigational eyedrop formulation containing copper intended for treatment of pediatric myopia. IVMED-85 will be the first eye drop inducing both scleral and corneal crosslinking for myopia control.


Lead Product(s): IVMED-85

Therapeutic Area: Ophthalmology Product Name: IVMED-85

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Recipient: iVeena

Deal Size: $0.3 million Upfront Cash: Undisclosed

Deal Type: Funding October 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. PTG-630 has demonstrated remarkable potency as an AGE inhibitor.


Lead Product(s): PTG-630

Therapeutic Area: Neurology Product Name: PTG-630

Highest Development Status: PreclinicalProduct Type: Small molecule

Recipient: Praetego

Deal Size: $0.3 million Upfront Cash: Undisclosed

Deal Type: Funding March 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TRE-515 is a novel first-in-class drug, which has been shown to prevent demyelination, and even facilitate remyelination, in multiple demyelinating disease mouse models. Furthermore, the FDA has designated TRE-515 an Orphan Drug in the treatment of ON.


Lead Product(s): TRE-515

Therapeutic Area: Oncology Product Name: TRE-515

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Trethera

Deal Size: $1.6 million Upfront Cash: Undisclosed

Deal Type: Funding October 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Infusions of purified IL-27 regulatory B cells (I27-Breg ) reduced symptoms in mouse models of multiple sclerosis (MS) and the eye disease autoimmune uveitis. The research suggests the cells may play a role in future human therapies.


Lead Product(s): I27-Breg

Therapeutic Area: Ophthalmology Product Name: I27-Breg

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 02, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY